Effect of aromatase inhibition on lipids and inflammatory markers of cardiovascular disease in elderly men with low testosterone levels

Clinical Endocrinology

Volumn 62, Issue 2, 2005, Pages 228-235

  Dougherty, Ryan H ^a   Rohrer, Jacqueline L ^a   Hayden, Douglas ^a   Rubin, Stephen D ^b,c   Leder, Benjamin Z ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b ASTRAZENECA   (United Kingdom)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; C REACTIVE PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; PLACEBO; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; AGING; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOUBLE BLIND PROCEDURE; ENZYME INHIBITION; ESTRADIOL BLOOD LEVEL; HUMAN; HYPOGONADISM; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCORING SYSTEM; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ANALYSIS OF VARIANCE; AROMATASE INHIBITORS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHI-SQUARE DISTRIBUTION; HOMEOSTASIS; HUMANS; HYPOGONADISM; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-6; LIPIDS; MALE; MIDDLE AGED; NITRILES; RISK FACTORS; TESTOSTERONE; TRIAZOLES; VASCULAR CELL ADHESION MOLECULE-1;

EID: 13444266495     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2005.02205.x     Document Type: Article

References (68)

1. Gray, A., Feldman, H.A., McKinlay, J.B. & Longcope, C. (1991) Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. Journal of Clinical Endocrinology and Metabolism, 73, 1016-1025.
2. Harman, S.M., Metter, E.J., Tobin, J.D., Pearson, J. & Blackman, M.R. (2001) Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. Journal of Clinical Endocrinology and Metabolism, 86, 724-731.
3. Morley, J.E., Kaiser, F.E., Perry, H.M. 3rd, Patrick, P., Morley, P.M., Stauber, P.M., Vellas, B., Baumgartner, R.N. & Garry, P.J. (1997) Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism, 46, 410-413.
4. Feldman, H.A., Longcope, C., Derby, C.A., Johannes, C.B., Araujo, A.B., Coviello, A.D., Bremner, W.J. & McKinlay, J.B. (2002) Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. Journal of Clinical Endocrinology and Metabolism, 87, 589-598.
5. Gray, A., Berlin, J.A., McKinlay, J.B. & Longcope, C. (1991) An examination of research design effects on the association of testosterone and male aging: results of a meta-analysis. Journal of Clinical Epidemiology, 44, 671-684.
6. Burns, A.S., Banks, S.M., Carter, C.S., Davidson, J.M. & Sherins, R.J. (1992) A long-term, prospective study of the physiologic and behavioral effects of hormone replacement in untreated hypogonadal men. Journal of Andrology, 13, 297-304.
7. Alexander, G.M., Swerdloff, R.S., Wang, C., Davidson, T., McDonald, V., Steiner, B. & Hines, M. (1998) Androgen-behavior correlations in hypogonadal men and eugonadal men. II. Cognitive abilities. Hormones and Behavior, 33, 85-94.
8. Christiansen, K. (1998) Behavioral correlates of testosterone. In: S. Nieschlag ed. Testosterone: Action, Deficiency, Substitution, 2nd edn. Springer, Berlin, 107-142.
9. Bhasin, S., Bross, R. & Storer, T. (1998) Androgens and muscles. In: S. Nieschlag ed. Testosterone: Action, Deficiency, Substitution, 2nd edn. Springer, Berlin, 209-227.
10. Finkelstein, J.S. (1998) Androgens and bone metabolism. In: S. Nieschlag ed. Testosterone: Action, Deficiency, Substitution, 2nd edn. Springer, Berlin, 187-207.
11. Jackson, J.A., Riggs, M.W. & Spiekerman, A.M. (1992) Testosterone deficiency as a risk factor for hip fractures in men: a case-control study. American Journal of Medical Science, 304, 4-8.
12. Morley, J.E., Perry, H.M. 3rd, Kaiser, F.E., Kraenzle, D., Jensen, J., Houston, K., Mattammal, M. & Perry, H.M. Jr. (1993) Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. Journal of the American Geriatrics Society, 41, 149-152.
13. Sih, R., Morley, J.E., Kaiser, F.E., Perry, H.M. 3rd, Patrick, P. & Ross, C. (1997) Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. Journal of Clinical Endocrinology and Metabolism, 82, 1661-1667.
14. Tenover, J.S. (1992) Effects of testosterone supplementation in the aging male. Journal of Clinical Endocrinology and Metabolism, 75, 1092-1098.
15. Hajjar, R.R., Kaiser, F.E. & Morley, J.E. (1997) Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. Journal of Clinical Endocrinology and Metabolism, 82, 3793-3796.
16. Snyder, P.J., Peachey, H., Hannoush, P., Berlin, JA., Loh, L., Lenrow, D.A., Holmes, J.H., Dlewati, A., Santanna, J., Rosen, C.J. & Strom, B.L. (1999) Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. Journal of Clinical Endocrinology and Metabolism, 84, 2647-2653.
17. Phillips, G.B., Pinkernell, B.H. & Jing, T.Y. (1994) The association of hypotestosteronemia with coronary artery disease in men. Arteriosclerosis and Thrombosis, 14, 701-706.
18. Yarnell, J.W., Beswick, A.D., Sweetnam, P.M. & Riad-Fahmy, D. (1993) Endogenous sex hormones and ischemic heart disease in men. The Caerphilly prospective study. Arteriosclerosis and Thrombosis, 13, 517-520.
19. Freedman, D.S., O'Brien, T.R., Flanders, W.D., DeStefano, F. & Barboriak, J.J. (1991) Relation of serum testosterone levels to high density lipoprotein cholesterol and other characteristics in men. Arteriosclerosis and Thrombosis, 11, 307-315.
20. Tan, K.C., Shiu, S.W., Pang, R.W. & Kung, A.W. (1998) Effects of testosterone replacement on HDL subfractions and apolipoprotein A-I containing lipoproteins. Clinical Endocrinology (Oxford), 48, 187-194.
21. Tan, K.C., Shiu, S.W. & Kung, A.W. (1999) Alterations in hepatic lipase and lipoprotein subfractions with transdermal testosterone replacement therapy. Clinical Endocrinology (Oxford), 51, 765-769.
22. Snyder, P.J., Peachey, H., Berlin, J.A., Rader, D., Usher, D., Loh, L., Hannoush, P., Dlewati, A., Holmes, J.H., Santanna, J. & Strom, B.L. (2001) Effect of transdermal testosterone treatment on serum lipid and apolipoprotein levels in men more than 65 years of age. American Journal of Medicine, 111, 255-260.
23. Kenny, A.M., Prestwood, K.M., Gruman, C.A., Fabregas, G., Biskup, B. & Mansoor, G. (2002) Effects of transdermal testosterone on lipids and vascular reactivity in older men with low bioavailable testosterone levels. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, 57, M460-M465.
24. Ng, M.K., Liu, P.Y., Williams, A.J., Nakhla, S., Ly, L.P., Handelsman, D.J. & Celermajer, D.S. (2002) Prospective study of effect of androgens on serum inflammatory markers in men. Arteriosclerosis, Thrombosis and Vascular Biology, 22, 1136-1141.
25. Hulley, S., Grady, D., Bush, T., Furberg, C., Herrington, D., Riggs, B. & Vittinghoff, E. (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Journal of the American Medical Association, 280, 605-613.
26. Manson, J.E., Hsia, J., Johnson, K.C., Rossouw, J.E., Assaf, A.R., Lasser, N.L., Trevisan, M., Black, H.R., Heckbert, S.R., Detrano, R., Strickland, O.L., Wong, N.D., Grouse, J.R., Stein, E. & Cushman, M., Women's Health Initiative Investigators. (2003) Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine, 349, 523-534.
27. Hodis, H.N., Mack, W.J., Azen, S.P., Lobo, R.A., Shoupe, D., Mahrer, P.R., Faxon, D.P., Cashin-Hemphill, L., Sanmarco, M.E., French, W.J., Shook, T.L., Gaarder, T.D., Mehra, A.O., Rabbani, R., Sevanian, A., Shil, A.B., Torres, M., Vogelbach, K.H., Selzer, R.H.; Women's Estrogen-Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trial Research Group. (2003) Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. New England Journal of Medicine, 349, 535-545.
28. Henriksson, P., Linde, B. & Edhag, O. (1987) Deleterious effects of low-dose oestrogen therapy on coronary status in patients with prostatic cancer. European Heart Journal, 8, 779-784.
29. Komesaroff, P.A., Fullerton, M., Esler, M.D., Dart, A., Jennings, G. & Sudhir, K. (2001) Low-dose estrogen supplementation improves vascular function in hypogonadal men. Hypertension, 38, 1011-1016.
30. Leder, B.Z., Rohrer, J.L., Longcope, C., Rubin, S.D., Gallo, J. & Finkelstein, J.S. (2004) Effects of aromatase inhibition in elderly men with mild hypogonadism. Journal of Clinical Endocrinology and Metabolism, 89, 1174-1180.
31. O'Connor, S., Baker, H.W, Dulmanis, A. & Hudson, B. (1973) The measurement of sex steroid binding globulin by differential ammonium sulphate precipitation. Journal of Steroid Biochemistry, 4, 331-339.
32. Korenman, S.G., Morley, J.E., Mooradian, A.D., Davis, S.S., Kaiser, F.E., Silver, A.J., Viosca, S.P. & Garza, D. (1990) Secondary hypogonadism in older men: its relation to impotence. Journal of Clinical Endocrinology and Metabolism, 71, 963-969.
33. Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F. & Turner, R.C. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28, 412-419.
34. Bonora, E., Targher, G., Alberiche, M., Bonadonna, R.C., Saggiani, F., Zenere, M.B., Monauni, T. & Muggeo, M. (2000) Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care, 23, 57-63.
35. Barret-Connor, E.L. (1995) Testosterone and risk factors for cardiovascular disease in men. Diabetes and Metabolism, 21, 156-161.
36. Hurley, B.F., Seals, D.R., Hagberg, J.M., Goldberg, A.C., Ostrove, S.M., Holloszy, J.O., Wiest, W.G. & Goldberg, A.P. (1984) High-density-lipoprotein cholesterol in bodybuilders v powerlifters. Negative effects of androgen use. Journal of the American Medical Association, 252, 507-513.
37. Thompson, P.D., Cullinane, E.M., Sady, S.P., Chenevert, C., Saritelli, A.L., Sady, M.A. & Herbert, P.N. (1989) Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. Journal of the American Medical Association, 261, 1165-1168.
38. Bhasin, S., Storer, T.W., Herman, N., Callegari, C., Clevenger, B., Phillips, J., Bunnell, T.J., Tricker, R., Shirazi, A. & Casaburi, R. (1996) The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. New England Journal of Medicine, 335, 1-7.
39. Singh, A.B., Hsia, S., Alaupovic, P., Sinha-Hikim, I., Woodhouse, L., Buchanan, T.A., Shen, R., Bross, R., Berman, N. & Bhasin, S. (2002) The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. Journal of Clinical Endocrinology and Metabolism, 87, 136-143.
40. Darling, G.M., Johns, J.A., McCloud, P.I. & Davis, S.R. (1997) Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. New England Journal of Medicine, 337, 595-601.
41. Walsh, B.W., Schiff, I., Rosner, B., Greenberg, L., Ravnikar, V. & Sacks, F.M. (1991) Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. New England Journal of Medicine, 325, 1196-1204.
42. Basdevant, A., De Lignieres, B. & Guy-Grand, B. (1983) Differential lipemic and hormonal responses to oral and parenteral 17 beta-estradiol in postmenopausal women. American Journal of Obstetrics and Gynecology, 147, 77-81.
43. Fahraeus, L. & Wallentin, L. (1983) High density lipoprotein subfractions during oral and cutaneous administration of 17 beta-estradiol to menopausal women. Journal of Clinical Endocrinology and Metabolism, 56, 797-801.
44. Vehkavaara, S., Silveira, A., Hakala-Ala-Pietila, T., Virkamaki, A., Hovatta, O., Hamsten, A., Taskinen, M.R. & Yki-Jarvinen, H. (2001) Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thrombosis and Haemostasis, 85, 619-625.
45. Wallentin, L. & Varenhorst, E. (1981) Plasma lipoproteins during anti-androgen treatment by estrogens or orchidectomy in men with prostatic carcinoma. Hormone and Metabolic Research, 13, 293-297.
46. Bulusu, N.V., Lewis, S.B., Das, S. & Clayton, W.E. Jr (1982) Serum lipid changes after estrogen therapy in prostatic carcinoma. Urology, 20, 147-150.
47. Moorjani, S., Dupont, A., Labrie, F., Lupien, P.J., Gagne, C., Brun, D., Giguere, M., Belanger, A. & Cusan, L. (1988) Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, estrogen, and combination treatment with luteinizing hormone-releasing hormone agonist and flutamide. Journal of Clinical Endocrinology and Metabolism, 66, 314-322.
48. Kunelius, P., Lukkarinen, O., Hannuksela, M.L., Itkonen, O. & Tapanainen, J.S. (2002) The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. Journal of Clinical Endocrinology and Metabolism, 87, 1467-1472.
49. Ross, R. (1999) Atherosclerosis - an inflammatory disease. New England Journal of Medicine, 340, 115-126.
50. Blake, G.J. & Ridker, P.M. (2002) Inflammatory bio-markers and cardiovascular risk prediction. Journal of Internal Medicine, 252, 283-294.
51. Ridker, P.M., Rifai, N., Stampfer, M.J. & Hennekens, C.H. (2000) Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation, 101, 1767-1772.
52. Ridker, P.M., Cushman, M., Stampfer, M.J., Tracy, R.P. & Hennekens, C.H. (1997) Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. New England Journal of Medicine, 336, 973-979.
53. Ridker, P.M., Hennekens, C.H., Buring, J.E. & Rifai, N. (2000) C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. New England Journal of Medicine, 342, 836-843.
54. Pradhan, A.D., Manson, J.E., Rossouw, J.E., Siscovick, D.S., Mouton, C.P., Rifai, N., Wallace, R.B., Jackson, R.D., Pettinger, M.S. & Ridker, P.M. (2002) Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. Journal of the American Medical Association, 288, 980-987.
55. Tedder, T.F., Steeber, D.A., Chen, A. & Engel, P. (1995) The selectins: vascular adhesion molecules. FASEB Journal, 9, 866-873.
56. Adams, D.H. & Shaw, S. (1994) Leucocyte-endothelial interactions and regulation of leucocyte migration. Lancet, 343, 831-836.
57. Blankenberg, S., Rupprecht, H.J., Bickel, C., Peetz, D., Hafner, G., Tiret, L. & Meyer, J. (2001) Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation, 104, 1336-1342.
58. McCrohon, J.A., Jessup, W., Handelsman, D.J. & Celermajer, D.S. (1999) Androgen exposure increases human monocyte adhesion to vascular endothelium and endothelial cell expression of vascular cell adhesion molecule-1. Circulation, 99, 2317-2322.
59. Hergenc, G., Schulte, H., Assmann, G. & von Eckardstein, A. (1999) Associations of obesity markers, insulin, and sex hormones with HDL-cholesterol levels in Turkish and German individuals. Atherosclerosis, 145, 147-156.
60. Tchernof, A., Labrie, F., Belanger, A. & Despres, J.P. (1996) Obesity and metabolic complications: contribution of dehydroepiandrosterone and other steroid hormones. Journal of Endocrinology, 150, S155-S164.
61. Tsai, E.C., Boyko, E.J., Leonetti, D.L. & Fujimoto, W.Y. (2000) Low serum testosterone level as a predictor of increased visceral fat in Japanese-American men. International Journal of Obesity and Related Metabolic Disorders, 24, 485-491.
62. Simon, D., Charles, M.A., Nahoul, K., Orssaud, G., Kremski, J., Hully, V., Joubert, E., Papoz, L. & Eschwege, E. (1997) Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: The Telecom Study. Journal of Clinical Endocrinology and Metabolism, 82, 682-685.
63. Snyder, P.J., Peachey, H., Berlin, J.A., Hannoush, P., Haddad, G., Dlewati, A., Santanna, J., Loh, L., Lenrow, D.A., Holmes, J.H., Kapoor, S.C., Atkinson, L.E. & Strom, B.L. (2000) Effects of testosterone replacement in hypogonadal men. Journal of Clinical Endocrinology and Metabolism, 85, 2670-2677.
64. Katznelson, L., Finkelstein, J.S., Schoenfeld, D.A., Rosenthal, D.I., Anderson, E.J. & Klibanski, A. (1996) Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. Journal of Clinical Endocrinology and Metabolism, 81,4358-4365.
65. Wang, C., Swedloff, R.S., Iranmanesh, A., Dobs, A., Snyder, P.J., Cunningham, G., Matsumoto, A.M., Weber, T. & Herman, N. (2000) Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Testosterone Gel Study Group. Journal of Clinical Endocrinology and Metabolism, 85, 2839-2853.
66. Marin, P., Holmang, S., Jonsson, L., Sjostrom, L., Kvist, H., Holm, G., Lindstedt, G. & Bjorntorp, P. (1992) The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. International Journal of Obesity and Related Metabolic Disorders, 16, 991-997.
67. Rebuffe-Scrive, M., Marin, P. & Bjorntorp, P. (1991) Effect of testosterone on abdominal adipose tissue in men. International Journal of Obesity, 15, 791-795.
68. Dieudonne, M.N., Pecquery, R., Leneveu, M.C. & Giudicelli, Y. (2000) Opposite effects of androgens and estrogens on adipogenesis in rat preadipocytes: evidence for sex and site-related specificities and possible involvement of insulin-like growth factor 1 receptor and peroxisome proliferator-activated receptor gamma2. Endocrinology, 141, 649-656.